Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Fast Is The Drug Eluting Balloons Catheters Market Expected to Grow Between 2025 And 2029?#_x000D_
In recent years, the market size of drug eluting balloons catheters has experienced significant growth. It is projected to rise from $1.43 billion in 2024 to $1.65 billion in 2025, representing a compound annual growth rate (CAGR) of 15.4%. The growth during the historical timeframe has been driven by factors such as escalating instances of respiratory disorders, the benefits of these catheters over conventional inhalers, patient inclination towards dpis, governmental efforts to improve respiratory health, strategic alliances and partnerships, drug formulation advancements, and a surging elderly population._x000D_
_x000D_
The market for drug eluting balloons catheters is projected to experience considerable expansion in the upcoming years, swelling to $2.62 billion in 2029, with a compound annual growth rate (CAGR) of 12.2%. The escalation in the projected period can be accounted for by consistent progression in respiratory disorders, a booming aging population, surging awareness and education, market proliferation in budding economies, bespoke medicine formulations, regulatory support and adherence, and advancements in packaging and design. Key trends over this period encompass the rise in use of smart inhalers and connecting technologies, a shift towards breath-actuated inhalers, concentration on the needs of pediatric and elderly patients, biologics delivery, and eco-friendly inhaler designs._x000D_
_x000D_
#Download a free sample to assess the report’s scope and structure:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=13429&type=smp_x000D_
_x000D_
#What are the Fundamental Drivers and Innovations Shaping the Drug Eluting Balloons Catheters Market?#_x000D_
The drug-eluting balloon catheter market is predicted to see an increase in growth, driven by the rising incidence of peripheral and cardiovascular diseases. Cardiovascular diseases (CVDs) relate to a series of conditions affecting the heart and blood vessels, whereas peripheral artery disease (PAD) commonly refers to a situation where narrowed arteries limit the blood flow to the limbs primarily. Drug-eluting balloon catheters offer a treatment option for coronary artery disease (CAD), using a semi-compliant angioplasty balloon covered with an anti-proliferative drug that can prevent re-narrowing of the vessel upon entry. For example, the Centers for Disease Control and Prevention, a US-based government organization, reported in May 2024 that heart disease caused the deaths of 702,880 individuals in 2022, corresponding to 1 out of every 5 deaths. Around 805,000 people suffer a heart attack annually in the United States, with 605,000 experiencing their first episode and 200,000 having had previous heart attacks. This increasing prevalence of peripheral and cardiovascular diseases is propelling the expansion of the drug-eluting balloon catheter market._x000D_
_x000D_
#How Is the Drug Eluting Balloons Catheters Market Segmented?#_x000D_
The drug eluting balloons cathetersmarket covered in this report is segmented – _x000D_
_x000D_
1) By Product: Coronary Artery Disease Drug-Eluting Balloon Catheters, Peripheral Vascular Disease Drug-Eluting Balloon Catheters_x000D_
2) By Drug: Paclitaxel, Sirolimus, Other Drugs_x000D_
3) By Raw Material: Nylon, Polyurethane, Other Raw Materials_x000D_
4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories_x000D_
_x000D_
Subsegments:_x000D_
1) By Coronary Artery Disease: Drug-Eluting Balloon Catheters, Plain Balloon Catheters_x000D_
2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters, Angioplasty Balloon Catheters_x000D_
3) By Angioplasty Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters_x000D_
_x000D_
#Request customized data on this market:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=13429&type=smp_x000D_
_x000D_
#Which Regions Are Driving the Next Phase of the Drug Eluting Balloons Catheters Market Growth?#_x000D_
North America was the largest region in the drug eluting balloons catheters market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#What Key Trends Are Shaping the Future of the Drug Eluting Balloons Catheters Market?#_x000D_
Key players in the drug-eluting balloon catheter sector are intensifying their focus on the creation of cutting-edge, next-gen products with superior technology to gain a leading position. An illustration of this is the March 2024 announcement by Boston Scientific Corporation, an American biomedical/biotechnology engineering company and global medical device manufacturer. They reported securing approval from the U.S. Food and Drug Administration (FDA) for their AGENT Drug-Coated Balloon (DCB). AGENT DCB, the pioneer drug-coated coronary balloon to be available in the U.S, is designed to treat in-stent restenosis (ISR), a condition characterized by plaque or scar tissue obstructing a stented vessel. Unique features of AGENT DCB include its paclitaxel coating which administers a therapeutic dose to the vessel wall, thereby reducing the recurrence of ISR without needing any extra stents or radiation. Trials in clinical settings indicated a 49% reduction in heart attack risk at the target location and manifested minimal rates of adverse incidents._x000D_
_x000D_
#View the full report here:#_x000D_
_x000D_
#How Is the Drug Eluting Balloons Catheters Market Defined and What Are Its Core Parameters?#_x000D_
A drug-eluting balloon catheter is a medical device used to treat coronary artery disease by percutaneous coronary intervention (PCI). It is a semi-compliant angioplasty balloon coated with an anti-proliferative drug that is released into the vessel wall during inflation, which helps to prevent restenosis and reduce the risk of late thrombosis without implanting a permanent foreign object._x000D_
_x000D_
#Purchase the full report and get a swift delivery:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13429_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Europe +44 7882 955267_x000D_
Asia & Others +44 7882 955267 & +91 8897263534_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model